Varma Manthena V S, Perumal Omathanu P, Panchagnula Ramesh
Department of Pharmaceutics, College of Pharmacy, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA.
Curr Opin Chem Biol. 2006 Aug;10(4):367-73. doi: 10.1016/j.cbpa.2006.06.015. Epub 2006 Jun 30.
P-glycoprotein (P-gp) associated multi-drug resistance is one of the major challenges in the chemotherapy of various cancers. On the other hand, it is now widely recognized that P-gp influences drug transport across various biological membranes. To this end, there is an increasing trend to optimize pharmacokinetics and drug delivery right from the initial stages of drug discovery by exploring all the possible mechanisms involved in 'deliverability'. Recent advances in molecular biology techniques and biochemical characterization methodologies have helped in identification of various transporters involved in absorption or secretion of drugs. P-gp, an efflux pump expressed along the gastrointestinal tract, limits the permeability of many drugs and thus affects their peroral absorption and bioavailability. A fundamental insight and thorough understanding of P-gp and its functional role in limiting drug absorption is critical to improve predictability of dynamic absorption models and aid in selection of new candidates for development, and also widen the scope of peroral delivery for 'challenging' molecules.
P-糖蛋白(P-gp)相关的多药耐药性是各种癌症化疗中的主要挑战之一。另一方面,现在人们普遍认识到P-gp会影响药物跨各种生物膜的转运。为此,从药物发现的初始阶段就通过探索“可递送性”中涉及的所有可能机制来优化药代动力学和药物递送的趋势日益增加。分子生物学技术和生化表征方法的最新进展有助于识别参与药物吸收或分泌的各种转运蛋白。P-gp是一种沿胃肠道表达的外排泵,它限制了许多药物的通透性,从而影响它们的口服吸收和生物利用度。对P-gp及其在限制药物吸收中的功能作用有基本的认识和透彻的理解,对于提高动态吸收模型的可预测性、帮助选择新的开发候选药物以及扩大“挑战性”分子的口服递送范围至关重要。